TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17431368

Group type: EXPERIMENTAL
Intervention: Androgen ablation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose escalation utilizing intensity modulated external beam radiation therapy or brachytherapy
Number of subjects: 0
Study: 16199414

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 6 microg kg(‐1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 12 microg kg(‐1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 45
Study: 12028119

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 10365192

Group type: EXPERIMENTAL
Intervention: Pergolide mesylate (12 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Risperidone (n = 9)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (2 weeks) followed by double-blind placebo-controlled design (24 weeks)
Number of subjects: 28
Study: 7740638

Group type: EXPERIMENTAL
Intervention: Stroke unit treatment using Bobath principles
Number of subjects: 65

Group type: COMPARATOR
Intervention: General medical unit treatment
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Stroke unit treatment
Number of subjects: 65
Study: 2161614

Group type: EXPERIMENTAL
Intervention: Diet A: 227 g canned beans daily in a single dose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diet B: 227 g canned beans daily in a divided dose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diet C: 182 g canned beans daily in a divided dose
Number of subjects: 24
Study: 7217721

Group type: EXPERIMENTAL
Intervention: Killed influenza virus vaccine (A/New Jersey/76)
Number of subjects: 25
Study: 30681712

Group type: EXPERIMENTAL
Intervention: READI2 (patient self-assessment combined with nurse assessment)
Number of subjects: 144868

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 144868

Group type: EXPERIMENTAL
Intervention: READI protocols (including READI1 and READI3)
Number of subjects: 144868
Study: 27979988

Group type: EXPERIMENTAL
Intervention: Histamine receptor antagonist
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Moderate treadmill exercise
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Histamine receptor blockade
Number of subjects: 49
Study: 25833732

Group type: EXPERIMENTAL
Intervention: CORDIAL cognitive behavioral/cognitive rehabilitation (CB/CR) program
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 201
Study: 24162809

Group type: EXPERIMENTAL
Intervention: RT + PCV chemotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: RT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patients' HRQOL
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cognition assessment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Progression-free patients' HRQOL
Number of subjects: 32
Study: 21134328

Group type: EXPERIMENTAL
Intervention: HPHchol diet (high-protein high-cholesterol); 590 mg cholesterol; 2 eggs per day; duration 12 weeks
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: HPHchol diet
Number of subjects: 65

Group type: COMPARATOR
Intervention: HPLchol diet (high-protein low-cholesterol); 213 mg cholesterol; replaced eggs with 100 g of lean animal protein; duration 12 weeks
Number of subjects: 65
Study: 19303978

Group type: COMPARATOR
Intervention: Control (0.04 g/min glucose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High (0.8 g/min glucose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-CHO diet without exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-CHO diet without exercise
Number of subjects: 6
Study: 19402905

Group type: EXPERIMENTAL
Intervention: Loozit group weight management program (G)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Loozit group weight management program plus additional therapeutic contact (G+ATC)
Number of subjects: 168
Study: 16137403

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, adjusted to 25 mg or 100 mg according to efficacy and toxicity)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 12045491

Group type: EXPERIMENTAL
Intervention: TDF 75 mg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: TDF 150 mg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: TDF 300 mg
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 10080461

Group type: EXPERIMENTAL
Intervention: Dalteparin (100 IU/kg before streptokinase and 120 IU/kg after 12 h)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Dalteparin (in patients with early reperfusion)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 101
Study: 7590049

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerotherapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation
Number of subjects: 90
Study: 2252186

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard facemask
Number of subjects: 48
Study: 7237926

Group type: COMPARATOR
Intervention: [14C]‐glycocholic acid (bolus injection or constant infusion)
Number of subjects: 21

Group type: COMPARATOR
Intervention: [14C]cholic acid
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: [14C]‐glycocholic acid
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Estimates of liver flow from [14C]glycocholic acid
Number of subjects: 21
Study: 30309008

Group type: EXPERIMENTAL
Intervention: counseling + application
Number of subjects: 833

Group type: COMPARATOR
Intervention: counseling
Number of subjects: 833
Study: 27007580

Group type: EXPERIMENTAL
Intervention: Gestational weight gain restriction program
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 302
Study: 24866329

Group type: EXPERIMENTAL
Intervention: sitagliptin
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: mitiglinide
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: mitiglinide/voglibose combination
Number of subjects: 29
Study: 22306193

Group type: EXPERIMENTAL
Intervention: AZD1236 75 mg twice daily for 6 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 20544348

Group type: EXPERIMENTAL
Intervention: OCC-walk (blood flow occlusion)
Number of subjects: 12
Study: 18371094

Group type: EXPERIMENTAL
Intervention: Early loading (test, n=16)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed loading (control, n=8)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Technical complications
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lingual gold onlay
Number of subjects: 24
Study: 16550603

Group type: EXPERIMENTAL
Intervention: Cisplatin administered intravenously (IV, 100 mg/m2)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cisplatin administered intra-arterially (IA, 150 mg/m2)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Higher GG adduct levels (>median) in primary tumor
Number of subjects: 35
Study: 12491212

Group type: EXPERIMENTAL
Intervention: Minocycline-ethylenediaminetetraacetate (M-EDTA) lock solution
Number of subjects: 14

Group type: COMPARATOR
Intervention: Heparin flush (Control)
Number of subjects: 14
Study: 10853165

Group type: EXPERIMENTAL
Intervention: Charnley prosthesis with an ogee flanged cup
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Spectron prosthesis with a metal backed cup
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: All 410 hips (combined analysis)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Expanded definition of failure including patient dissatisfaction
Number of subjects: 372

Group type: COMPARATOR
Intervention: Charnley prosthesis (Swedish National Hip Registry)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Spectron prosthesis (Swedish National Hip Registry)
Number of subjects: 372
Study: 8917004

Group type: EXPERIMENTAL
Intervention: 1% lignocaine infiltration into the subserosal aspect of the cornual end of the fallopian tubes
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal saline infiltration into the subserosal aspect of the cornual end of the fallopian tubes
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 1% lignocaine infiltration
Number of subjects: 59
Study: 1756285

Group type: EXPERIMENTAL
Intervention: Otilonium bromide (OB) 40 mg tid
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 7017982

Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg IV every 6 hours
Number of subjects: 300

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Antacid titration to maintain gastric pH > 4.0
Number of subjects: 300
Study: 31336262

Group type: EXPERIMENTAL
Intervention: High self-focused attention (focusing on a disliked part in a mirror placed 10 cm away)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Low self-focused attention (looking into a mirror placed 100 cm away)
Number of subjects: 51
Study: 29457034

Group type: EXPERIMENTAL
Intervention: Unilateral arm crank exercise test
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Leg cycle exercise test
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 16
Study: 26450680

Group type: EXPERIMENTAL
Intervention: Late dinner group (dinner at 22:30 h)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Early dinner group (dinner at 17:30 h)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Late dinner group
Number of subjects: 14

Group type: COMPARATOR
Intervention: Early dinner group
Number of subjects: 14
Study: 24252475

Group type: EXPERIMENTAL
Intervention: Guided CBT self-help classes (Living Life to the Full - LLTTF), delivered over eight sessions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed access to guided CBT self-help classes (Living Life to the Full - LLTTF), delivered over eight sessions.
Number of subjects: 0
Study: 21328472

Group type: EXPERIMENTAL
Intervention: Brindley stimulator
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 93
Study: 19641042

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by concurrent chemoradiation in SCCHN patients (TAX 324 trial)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: HPV-positive oropharyngeal cancer patients
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: HPV status assessment
Number of subjects: 106

Group type: COMPARATOR
Intervention: Non-oropharyngeal SCCHN patients
Number of subjects: 106

Group type: COMPARATOR
Intervention: HPV-negative patients
Number of subjects: 106
Study: 17605495

Group type: EXPERIMENTAL
Intervention: RMCC appliance
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Class II elastics on UAs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (untreated persons)
Number of subjects: 30
Study: 15486384

Group type: EXPERIMENTAL
Intervention: Upper-body strength training
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 67
Study: 11564014

Group type: EXPERIMENTAL
Intervention: Shock waves focused on the end of the contrast medium column (Group 1)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Shock waves focused 5 mm beyond the end of the contrast medium column (Group 2)
Number of subjects: 156
Study: 9783350

Group type: EXPERIMENTAL
Intervention: 50 mg/day sertraline
Number of subjects: 40

Group type: COMPARATOR
Intervention: 150 mg/day imipramine
Number of subjects: 40
Study: 7838913

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (25 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3279969

Group type: EXPERIMENTAL
Intervention: Complamin (1 g t.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholestyramine (4 g b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Complamin and cholestyramine
Number of subjects: 0
Study: 31232638

Group type: EXPERIMENTAL
Intervention: Flat stimuli at -5 dB SNR
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Flat and staircase stimuli in all SNRs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: P1 and N1 latencies due to noisy CAEPs
Number of subjects: 13
Study: 28395845

Group type: EXPERIMENTAL
Intervention: Complementary feeding at 4 months corrected age
Number of subjects: 403

Group type: COMPARATOR
Intervention: Complementary feeding at 6 months corrected age
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Hospital admissions
Number of subjects: 403
Study: 25735313

Group type: EXPERIMENTAL
Intervention: Treadmill training with Tilt Sensor FES (TTSF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treadmill training with Placebo Tilt Sensor FES (TPTSF)
Number of subjects: 30
Study: 23587943

Group type: EXPERIMENTAL
Intervention: Artesunate plus sulfadoxine-pyrimethamine (AS+SP) with primaquine (0.75 mg/kg) on day 2
Number of subjects: 1335

Group type: COMPARATOR
Intervention: Artesunate plus sulfadoxine-pyrimethamine (AS+SP) alone
Number of subjects: 1335
Study: 21512491

Group type: EXPERIMENTAL
Intervention: Topical application of IRS 19
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irrigation of the nasopharynx with saline solutions
Number of subjects: 0
Study: 19146567

Group type: EXPERIMENTAL
Intervention: TRIP intervention
Number of subjects: 12
Study: 17002812

Group type: EXPERIMENTAL
Intervention: Unilateral lower limb suspension (ULLS) for 20 days
Number of subjects: 8
Study: 15177863

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care
Number of subjects: 28

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 28
Study: 11672942

Group type: EXPERIMENTAL
Intervention: Oral flupenthixol (2.5 or 5.0 mg; p.o.)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intramuscular flupenthixol decanoate (10 or 20 mg; i.m.)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High dose flupenthixol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9389840

Group type: EXPERIMENTAL
Intervention: Sevoflurane (maximum inspired concentration 8%)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Halothane (maximum inspired concentration 5%)
Number of subjects: 100
Study: 8179047

Group type: EXPERIMENTAL
Intervention: Restricted work-site smoking policy
Number of subjects: 67
Study: 3034040

Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 to 10 mg daily) - once-daily administration
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 to 10 mg daily) - twice-daily administration
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 to 10 mg daily)
Number of subjects: 39
Study: 29354931

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mulligan's mobilization
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined therapy (EA + Mulligan's mobilization)
Number of subjects: 120
Study: 27319970

Group type: EXPERIMENTAL
Intervention: ABT‐126 50 mg
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study: 26280376

Group type: EXPERIMENTAL
Intervention: Expand Your Horizon programme
Number of subjects: 81

Group type: COMPARATOR
Intervention: Active control programme
Number of subjects: 81
Study: 23660378

Group type: EXPERIMENTAL
Intervention: 2.4 g AA kg(‐1) · d(‐1) plus 2‐3 g lipids kg(‐1) · d(‐1) (AA + lipid group)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 3.6 g AA kg(‐1) · d(‐1) plus 2‐3 g lipids kg(‐1) · d(‐1) (high AA + lipid group)
Number of subjects: 144

Group type: COMPARATOR
Intervention: 2.4 g AA kg(‐1) · d(‐1) (control group)
Number of subjects: 144
Study: 21908683

Group type: EXPERIMENTAL
Intervention: Embolic protection device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Platelet glycoprotein IIb/IIIa inhibitor
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined treatment with abciximab and Angioguard(®) embolic protection
Number of subjects: 100
Study: 18162662

Group type: EXPERIMENTAL
Intervention: Female-relevant content domain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male-relevant content domain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational manipulations
Number of subjects: 0
Study: 16787523

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CGMS
Number of subjects: 27
Study: 14711164

Group type: EXPERIMENTAL
Intervention: Self-report measures of condom use
Number of subjects: 0
Study: 11471077

Group type: EXPERIMENTAL
Intervention: TRA1 (Trachoma Rapid Assessment 1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: TRA2 (Trachoma Rapid Assessment 2)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Door-to-door survey
Number of subjects: 13
Study: 9551726

Group type: EXPERIMENTAL
Intervention: Postal smoking cessation advice from a respiratory physician with person-specific health advice and a pamphlet on smoking cessation, n=1,300
Number of subjects: 2610

Group type: COMPARATOR
Intervention: Control group with no information, n=1,310
Number of subjects: 2610

Group type: EXPERIMENTAL
Intervention: Postal smoking cessation advice from a respiratory physician, n=1,300
Number of subjects: 2610
Study: 7999812

Group type: EXPERIMENTAL
Intervention: Intraperitoneal antibiotics (Cephalothin, cefazolin, vancomycin, ceftazidime, aminoglycosides tobramycin and gentamicin)
Number of subjects: 1930

Group type: EXPERIMENTAL
Intervention: Aminoglycosides alone
Number of subjects: 1930

Group type: EXPERIMENTAL
Intervention: Single drug therapy
Number of subjects: 1930

Group type: EXPERIMENTAL
Intervention: Initial intraperitoneal therapy for both gram-positive and gram-negative bacteria
Number of subjects: 1930
Study: 3057482

Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene (DXP) 130 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene (DXP) 65 mg + Amitriptyline (AMI) 25 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Indomethacin (IN) 50 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31757517

Group type: EXPERIMENTAL
Intervention: Non-fatal overdose (NFOD) incidence after release from prison
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: Recent history of substance use disorder (SUD)
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: Dual diagnosis of mental illness and SUD
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: Lifetime history of injecting drug use
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: Lifetime history of NFOD
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: Being dispensed benzodiazepines after release
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: Shorter index incarceration
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: Low perceived social support
Number of subjects: 1307

Group type: COMPARATOR
Intervention: High-risk alcohol use
Number of subjects: 1307

Group type: COMPARATOR
Intervention: While incarcerated
Number of subjects: 1307
Study: 29872112

Group type: EXPERIMENTAL
Intervention: Therapeutic sleep deprivation (SD) for 36 hours
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Therapeutic sleep deprivation (SD)
Number of subjects: 93
Study: 27989008

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Local Anesthetic (LA)/Corticosteroid
Number of subjects: 46
Study: 26559317

Group type: EXPERIMENTAL
Intervention: Andexanet bolus for apixaban (24 participants)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo for apixaban (9 participants)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Andexanet bolus for rivaroxaban (27 participants)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo for rivaroxaban (14 participants)
Number of subjects: 74
Study: 24285938

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg/day for 8 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg/day for 8 weeks
Number of subjects: 60
Study: 20833759

Group type: EXPERIMENTAL
Intervention: Stress management intervention (SMI)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 174
Study: 18344636

Group type: EXPERIMENTAL
Intervention: Transdermal tulobuterol patch (TP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Slow-release theophylline
Number of subjects: 16
Study: 16864110

Group type: EXPERIMENTAL
Intervention: Deoxyribonucleotidum injection
Number of subjects: 80
Study: 12704355

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 30 mg (n = 464)
Number of subjects: 935

Group type: COMPARATOR
Intervention: Placebo (n = 471)
Number of subjects: 935
Study: 10634340

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard treatment with supplemental oxygen
Number of subjects: 40
Study: 9385125

Group type: EXPERIMENTAL
Intervention: Beclomethasone (200 microg twice daily)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg twice daily)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Beclomethasone
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 241
Study: 1348061

Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg, four times daily for 3 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 17
Study: 30412281

Group type: EXPERIMENTAL
Intervention: S5 methylation testing
Number of subjects: 257

Group type: COMPARATOR
Intervention: Combined abnormal cytology/HPV16/18 positivity
Number of subjects: 257
Study: 30605935

Group type: EXPERIMENTAL
Intervention: JOAG patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 25